Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced today that it has entered into an initial 12-month collaborative agreement with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), a Division of Janssen Pharmaceutica N.V.
